A Platform Stratifying a Sequestering Agent and a Pharmacological Antagonist as a Means to Negate Botulinum Neurotoxicity

ACS Chemical Neuroscience

Volumn 5, Issue 8, 2014, Pages 632-636

  Harris, Tyler L ^a   Lowery, Colin A ^a   Hixon, Mark S ^b   Janda, Kim D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Takeda San Diego Inc   (United States)

Author keywords

antibody; Botulinum neurotoxin; drug combination; prodrug

Indexed keywords

3,4 DIAMINOPYRIDINE; BOTULINUM TOXIN A; POLYCLONAL ANTIBODY; SEQUESTERING AGENT; 3,4-DIAMINOPYRIDINE; BOTULINUM ANTISERUM; BOTULINUM TOXIN; FAMPRIDINE; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; LETHALITY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MUSCLE CONTRACTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; DRUG COMBINATION; KINETICS; NEUROTOXICITY SYNDROMES; SURVIVAL;

4-AMINOPYRIDINE; ANIMALS; BOTULINUM ANTITOXIN; BOTULINUM TOXINS; DRUG THERAPY, COMBINATION; FEMALE; KINETICS; MICE; NEUROTOXICITY SYNDROMES; POTASSIUM CHANNEL BLOCKERS; SEQUESTERING AGENTS; SURVIVAL ANALYSIS;

EID: 84906254406     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500135h     Document Type: Article

References (20)

1. Johnson, E. A. and Bradshaw, M. (2001) Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective Toxicon 39, 1703-1722
2. Madsen, J. M. (2001) Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents Clin. Lab. Med. 21, 593-605
3. Schantz, E. J. and Johnson, E. A. (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine Microbiol. Mol. Biol. Rev. 56, 80-99
4. Oguma, K., Fuginaga, Y., and Inoue, K. (1995) Structure and Function of Clostridium botulinum Toxins Microbiol. Immunol. 39, 161-168
5. Willis, B., Eubanks, L. M., Dickerson, T. J., and Janda, K. D. (2008) The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison Angew. Chem., Int. Ed. 47, 8360-8379
6. Al-Saleem, F. H., Nasser, Z., Olson, R. M., Cao, L., and Simpson, L. L. (2011) Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare J. Pharmacol. Exp. Ther. 338, 503-517
7. Arnon, S. S., Schechter, R., Maslanka, S. E., Jewell, N. P., and Hatheway, C. L. (2006) Human botulism immune globulin for the treatment of infant botulism N. Engl. J. Med. 354, 462-471
8. Simpson, L. L. (2013) The life history of a botulinum toxin molecule Toxicon 68, 40-59
9. Seki, H., Pellett, S., Silhar, P., Stowe, G. N., Blanco, B., Lardy, M. A., Johnson, E. A., and Janda, K. D. (2014) Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain Bioorg. Med. Chem. 22, 1208-1217
10. Mayorov, A. V., Willis, B., Di Mola, A., Adler, D., Borgia, J., Jackson, O., Wang, J., Luo, Y., Knapp, R. J., Nataragan, C., Goodnough, M. C., Zilberberg, N., Simpson, L. L., and Janda, K. D. (2010) Symptomatic relief of botulinum neurotoxin/a intoxication with aminopyridines: a new twist on an old molecule ACS Chem. Biol. 5, 1183-1191
11. Adler, M., Macdonald, D. A., Sellin, L. C., and Parker, G. W. (1996) Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin Toxicon 34, 237-249
12. Lowery, C. A., Adler, M., Borrell, A., and Janda, K. D. (2013) Scorpion toxins for the reversal of BoNT-induced paralysis Bioorg. Med. Chem. Lett. 23, 6743-3746
13. Foran, P. G., Mohammad, N., Lisk, G. O., Nagwaney, S., Lawrence, G. W., Johnson, E., Smith, L., Aoki, K. R., and Dolly, J. O. (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons J. Biol. Chem. 278, 1363-1371
14. Adler, M., Scovill, J., Parker, G., Lebeda, F. J., Piotrowski, J., and Deshpande, S. S. (1995) Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations Toxicon 33, 527-537
15. Molgo, J., Lemeignan, M., Lechat, P., and Peradejordi, F. (1985) Increase in evoked transmitter release from motor nerve terminals by some amino N-heterocyclic compounds Eur. J. Med. Chem. 20, 149-153
16. Adler, M., Capacio, B., and Deshpande, S. S. (2000) Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps Toxicon 38, 1381-1388
17. Zakhari, J. S., Kinoyama, I., Hixon, M. S., Di Mola, A., Globisch, D., and Janda, K. D. (2011) Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization Bioorg. Med. Chem. 19, 6203-6209
18. Kelder, J., Grootenhuis, P. D., Bayada, D. M., Delbressine, L. P., and Ploeman, J. P. (1999) Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 16, 1514-1519
19. Vig, B. S., Huttunen, K. M., Laine, K., and Rautio, J. (2013) Amino acids as promoieties in prodrug design and development Adv. Drug Delivery Rev. 65, 1370-1385
20. Uhrich, K. E. (1999) Polymeric Systems for Controlled Drug Release Chem. Rev. 99, 3181-3198